Study Name:
A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using Exablate focused ultrasound during the standard of care treatment of brain metastases of non-small cell lung cancer (NSCLC) origin
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The primary objective is to evaluate the safety and efficacy of blood brain barrier disruption using the Exablate Type 2 system in adult subjects with brain metastases of NSCLC origin that are either undergoing or have planned standard of care pembrolizumab monotherapy as compared to subjects that are undergoing standard of care pembrolizumab without Exablate blood brain barrier disruption.
Study Dates:
August 12, 2022 - December 30, 2024
Study Location:
Nationwide
Lead Institution:
Miami Cancer Institute, Baptist Health South Florida
Funding Source:
Insightec
Sponsors:
Insightec
Contact:
Contact Phone: 774-266-6280
Contact Email: [email protected]
ClinicalTrails.gov Identifier:
NCT05317858
Sponsor:
Insightec
Contact:
Contact Phone: 774-266-6280
Contact Email: [email protected]
